PriceTargets.com logo

Mural Oncology - MURA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 337.16%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$3.66 As of 03/13/2025 05:00 PM ET
▼ -0.07 (-1.88%)

This chart shows the closing price for MURA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$3.66Closing price on 03/13/25:
Get New Mural Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MURA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MURA

Analyst Price Target is $16.00
▲ +337.16% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Mural Oncology in the last 3 months. The average price target is $16.00, with a high forecast of $18.00 and a low forecast of $13.00. The average price target represents a 337.16% upside from the last price of $3.66.

This chart shows the closing price for MURA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/253/26$2.08$6.06$10$14$18Closing price on 03/13/25: $3.66High$18.00Average$16.00Low$13.00




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Mural Oncology.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2025

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
10/17/2024HC WainwrightInitiated CoverageBuy$18.00
10/4/2024Raymond JamesInitiated CoverageStrong-Buy$18.00
6/28/2024Rodman & RenshawInitiated CoverageBuy$15.00
4/4/2024Morgan StanleyInitiated CoverageOverweight$13.00
(Data available from 3/14/2020 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
Mentions as of
8/16/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2024
  • 10 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2024
  • 8 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
11/14/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/13/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/14/2025

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Mural Oncology logo
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $3.66
Low: $3.63
High: $3.75

50 Day Range

MA: $3.85
Low: $3.20
High: $4.47

52 Week Range

Now: $3.66
Low: $2.87
High: $5.23

Volume

74,827 shs

Average Volume

161,191 shs

Market Capitalization

$62.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Mural Oncology?

The following equities research analysts have issued reports on Mural Oncology in the last twelve months: HC Wainwright, Morgan Stanley, Raymond James, and Rodman & Renshaw.
View the latest analyst ratings for MURA.

What is the current price target for Mural Oncology?

0 Wall Street analysts have set twelve-month price targets for Mural Oncology in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 337.2%. Raymond James has the highest price target set, predicting MURA will reach $18.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $13.00 for Mural Oncology in the next year.
View the latest price targets for MURA.

What is the current consensus analyst rating for Mural Oncology?

Mural Oncology currently has 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MURA will outperform the market and that investors should add to their positions of Mural Oncology.
View the latest ratings for MURA.

What other companies compete with Mural Oncology?

Other companies that are similar to Mural Oncology include Atea Pharmaceuticals, Foghorn Therapeutics, Aurora Cannabis, Neumora Therapeutics and Amylyx Pharmaceuticals. Learn More about companies similar to Mural Oncology.

How do I contact Mural Oncology's investor relations team?

The company's listed phone number is 353-1-905-8020 and its investor relations email address is ir@muraloncology.com. The official website for Mural Oncology is www.muraloncology.com. Learn More about contacing Mural Oncology investor relations.